• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients.

作者信息

Vreugdenhil G, Swaak A J, Kontoghiorghes G J, van Eijk H G

出版信息

Lancet. 1989 Dec 9;2(8676):1398-9. doi: 10.1016/s0140-6736(89)92011-4.

DOI:10.1016/s0140-6736(89)92011-4
PMID:2574342
Abstract
摘要

相似文献

1
Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients.口服铁螯合剂L1对类风湿性关节炎贫血患者的疗效及安全性
Lancet. 1989 Dec 9;2(8676):1398-9. doi: 10.1016/s0140-6736(89)92011-4.
2
Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one(L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis.口服铁螯合剂1,2-二甲基-3-羟基吡啶-4-酮（L1）与转铁蛋白之间的铁交换相关性以及L1在类风湿性关节炎中的可能抗贫血作用。
Ann Rheum Dis. 1990 Nov;49(11):956-7. doi: 10.1136/ard.49.11.956-b.
3
Clinical trials with oral iron chelator L1.口服铁螯合剂L1的临床试验。
Lancet. 1989;2(8678-8679):1516-7. doi: 10.1016/s0140-6736(89)92952-8.
4
Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.
Ann N Y Acad Sci. 1990;612:369-77. doi: 10.1111/j.1749-6632.1990.tb24324.x.
5
Future of oral iron chelator deferiprone. (L1) ICOC committee.口服铁螯合剂去铁酮的未来。（L1）国际铁过载并发症委员会。
Lancet. 1993 Jun 5;341(8858):1479-80. doi: 10.1016/0140-6736(93)90925-7.
6
Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).使用口服活性铁螯合剂去铁酮（L1）对地中海贫血患者进行螯合治疗。
Haematologica. 2000 Feb;85(2):115-7.
7
Arthropathy in thalassaemia patients receiving deferiprone.
Lancet. 1994 Jun 11;343(8911):1471-2. doi: 10.1016/s0140-6736(94)92585-2.
8
Safety of oral iron chelator L1.口服铁螯合剂L1的安全性。
Lancet. 1989 Aug 19;2(8660):457-8. doi: 10.1016/s0140-6736(89)90642-9.
9
Future of oral iron chelator deferiprone (L1).口服铁螯合剂去铁酮（L1）的未来。
Lancet. 1993 Jun 5;341(8858):1480.
10
Agranulocytosis and thrombocytopenia, Blackfan-Diamond anaemia, and oral chelation.
Lancet. 1990 Apr 21;335(8695):970. doi: 10.1016/0140-6736(90)91031-5.

引用本文的文献

1
New Approaches and Strategies for the Repurposing of Iron Chelating/Antioxidant Drugs for Diseases of Free Radical Pathology in Medicine.铁螯合/抗氧化药物在医学中用于自由基病理疾病的重新利用的新方法和策略。
Antioxidants (Basel). 2025 Aug 10;14(8):982. doi: 10.3390/antiox14080982.
2
Ferroptosis, a therapeutic target for cardiovascular diseases, neurodegenerative diseases and cancer.铁死亡，一种针对心血管疾病、神经退行性疾病和癌症的治疗靶点。
J Transl Med. 2024 Dec 22;22(1):1137. doi: 10.1186/s12967-024-05881-6.
3
The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.
天然和合成螯合剂在医学中的重要性和必要性：有效治疗铁过载和缺铁症的前景增加。
Int J Mol Sci. 2024 Apr 25;25(9):4654. doi: 10.3390/ijms25094654.
4
Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.药物选择和剂量、医学中的最佳治疗和风险/效益评估：铁螯合剂药物的范例。
Int J Mol Sci. 2023 Nov 25;24(23):16749. doi: 10.3390/ijms242316749.
5
Identification of potential ferroptosis key genes and immune infiltration in rheumatoid arthritis by integrated bioinformatics analysis.通过综合生物信息学分析鉴定类风湿关节炎中潜在的铁死亡关键基因和免疫浸润
Heliyon. 2023 Oct 18;9(11):e21167. doi: 10.1016/j.heliyon.2023.e21167. eCollection 2023 Nov.
6
The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases.去铁酮在将地中海贫血从致命疾病转变为慢性疾病过程中所起的关键作用及其在非铁过载疾病中重新应用面临的挑战
Pharmaceuticals (Basel). 2023 Jul 18;16(7):1016. doi: 10.3390/ph16071016.
7
Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects.地拉罗司和铁-麦芽酚：从发现到药物设计、研发、临床应用及未来前景的四十年。
Int J Mol Sci. 2023 Mar 4;24(5):4970. doi: 10.3390/ijms24054970.
8
New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer.新型铁代谢途径和螯合靶向策略影响各种类型和阶段癌症的治疗。
Int J Mol Sci. 2022 Nov 13;23(22):13990. doi: 10.3390/ijms232213990.
9
Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology.地拉罗司：一种具有 40 年历史的多靶点药物，可能对 COVID-19 和具有相似症状的疾病具有活性。
Int J Mol Sci. 2022 Jun 16;23(12):6735. doi: 10.3390/ijms23126735.
10
Questioning Established Theories and Treatment Methods Related to Iron and Other Metal Metabolic Changes, Affecting All Major Diseases and Billions of Patients.质疑与铁及其他金属代谢变化相关的既定理论和治疗方法，影响所有主要疾病和数十亿患者。
Int J Mol Sci. 2022 Jan 25;23(3):1364. doi: 10.3390/ijms23031364.